ClinicalTrials.gov
public full text
Public Domain
Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors
adenocarcinomaadvanced-solid-tumorsendometrial-cancerhead-and-neck-cancerlung-cancerovarian-cancerprostate-cancersolid-tumors
This is a Phase I study to test the safety, pharmacokinetics and effectiveness of STM 434 alone, or in combination with liposomal doxorubicin, in patients with ovarian cancer or other advanced solid tumors.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Combination Therapy for Recurrent Ovarian Cancer#862994
- SGI-110 in Combination With Carboplatin in Ovarian Cancer#839915
- Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer#829752
- S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer#807707
- Doxorubicin Hydrochloride Liposome and Carboplatin in Treating Patients With Recurrent, Stage III, or Stage IV Primary Endometrial Cancer#828419
Record · ID 802430
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive